Back to top

Analyst Blog

We downgrade our recommendation on The Cooper Companies (COO - Analyst Report) to Neutral following its fiscal fourth quarter (ended October 31) results. Its fourth-quarter fiscal 2012 adjusted earnings per share rose 0.7% year over year to a record high of $1.47. However, it missed the Zacks Consensus Estimate of $1.53.

Revenues in the fourth quarter increased 10% (up 7% in constant currency, barring acquisitions) year over year to $396.3 million, falling short of the Zacks Consensus Estimate of $398 million. Growth was led by robust sales of offerings from CooperSurgical (CSI), higher revenues from CooperVision (CVI), acquisition synergies and newer products.

Revenues from Cooper’s mainstay contact lens division (80.3% of company-wide revenues), CVI edged up 5% (up 7% in constant currency) year over year at $318.1 million. Sales were higher for all categories of lenses. On a material based analysis, sales of silicone hydrogel contact lenses were up sharply 24% in constant currency to $124 million while Proclear contact lens sales edged up 4% to $80.4 million.

The smaller women’s health segment (19.7% of company-wide revenues) CSI performed well with revenues soaring 37% year over year (up 2% barring acquisitions) to $78.2 million. Cooper witnessed mixed contributions from operating units under its CSI segment.

Cooper, a global medical products company, specializes in a wide range of contact lenses for the vision correction market with a smaller strategic business unit for women’s health. It reportedly holds the number three position in the $6 billion global contact lens industry.

The company is a leader in the high-margin toric lens market. It offers multiple designs of toric lenses, across a wide range of parameters, unlike some of its competitors, who offer toric lenses in a limited number of designs. Cooper is benefiting from strong demand for its toric lenses.

However, Cooper faces formidable competition in each of its major product lines. Competition comes from well established global contact lens makers such as Johnson & Johnson (JNJ - Analyst Report) and Novartis (NVS - Analyst Report). Depressed levels of consumer spending have heightened the company’s competitive pressures. The stock currently retains a Zacks #2 Rank, which translates into a short-term “Buy” recommendation.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ERBA DIAGNO… ERB 3.80 +7.04%
BANCO DO BR… BDORY 14.74 +5.66%
AIR INDUSTR… AIRI 9.99 +4.15%
EQT MIDSTRE… EQM 98.14 +3.38%
WEATHERFORD… WFT 23.64 +3.10%